Efficacy of Tocilizumab in Patients With COVID-19 ARDS Undergoing Noninvasive Ventilation

Francesco Menzella; Matteo Fontana; Carlo Salvarani; Marco Massari; Patrizia Ruggiero; Chiara Scelfo; Chiara Barbieri; Claudia Castagnetti; Chiara Catellani; Giorgia Gibellini; Francesco Falco; Giulia Ghidoni; Francesco Livrieri; Gloria Montanari; Eleonora Casalini; Roberto Piro; Pamela Mancuso; Luca Ghidorsi; Nicola Facciolongo


Crit Care. 2020;24(589) 

In This Article


In summary, our preliminary data show that TCZ is effective in COVID-19 patients with severe respiratory impairment underlying NIV with a significant reduction in the proportion of patients who died in the pulmonology unit or were intubated. This may represent a subgroup of patients in which TCZ is particularly effective. However, regarding safety, in particular the increased risk of developing superinfections, more data are needed. Multicenter randomized controlled studies enrolling large series of patients are needed to confirm the efficacy and safety of TCZ in COVID-19 patients with respiratory involvement of different severity levels and to evaluate if there are differences in efficacy between SC and IV formulation of this drug.